EPLIN Expression in Gastric Cancer and Impact on Prognosis and Chemoresistance

Epithelial protein lost in neoplasm (EPLIN) has been implicated as a suppressor of cancer progression. The current study explored EPLIN expression in clinical gastric cancer and its association with chemotherapy resistance. EPLIN transcript expression, in conjunction with patient clinicopathological information and responsiveness to neoadjuvant chemotherapy (NAC), was explored in two gastric cancer cohorts collected from the Beijing Cancer Hospital. Kaplan-Meier survival analysis was undertaken to explore EPLIN association with patient survival. Reduced EPLIN expression was associated with significant or near significant reductions of overall, disease-free, first progression or post-progression survival in the larger host cohort and Kaplan Meier plotter datasets. In the larger cohort EPLIN expression was significantly higher in the combined T1 + T2 gastric cancer group compared to the T3 + T4 group and identified to be an independent prognostic factor of disease-free survival and overall survival by multivariate analysis. In the smaller, NAC cohort, EPLIN expression was found to be significantly lower in tumour tissues than in paratumour tissues. EPLIN expression was significantly associated with responsiveness to chemotherapy which contributes to overall survival. Together, EPLIN appears to be a prognostic factor and may be associated with patient sensitivity to NAC.

[1]  H. El‐Serag,et al.  Burden of Gastric Cancer. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  S. Rubtsova,et al.  Early Events in Actin Cytoskeleton Dynamics and E-Cadherin-Mediated Cell-Cell Adhesion during Epithelial-Mesenchymal Transition , 2020, Cells.

[3]  A. Ardizzoni,et al.  Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis. , 2019, Future oncology.

[4]  K. Rottner,et al.  EPLIN-α and -β Isoforms Modulate Endothelial Cell Dynamics through a Spatiotemporally Differentiated Interaction with Actin. , 2019, Cell reports.

[5]  F. Buonaguro,et al.  Precision medicine in gastric cancer , 2019, World journal of gastrointestinal oncology.

[6]  F. Cianchi,et al.  Update on gastric cancer treatments and gene therapies , 2019, Cancer and Metastasis Reviews.

[7]  Yaoyu E. Wang,et al.  Loss of Tight Junction Protein Claudin 18 Promotes Progressive Neoplasia Development in Mouse Stomach. , 2018, Gastroenterology.

[8]  W. Jiang,et al.  Mechanistic insights of epithelial protein lost in neoplasm in prostate cancer metastasis , 2018, International journal of cancer.

[9]  S. Cascinu,et al.  Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. , 2018, International journal of surgery.

[10]  B. Baradaran,et al.  Circulating MicroRNAs: Valuable Biomarkers for the Diagnosis and Prognosis of Gastric Cancer. , 2017, Current medicinal chemistry.

[11]  H. Jung,et al.  Risk factors for early metachronous tumor development after endoscopic resection for early gastric cancer , 2017, PloS one.

[12]  Daqing Wu.  Epithelial protein lost in neoplasm (EPLIN): Beyond a tumor suppressor , 2017, Genes & diseases.

[13]  Y. Sasaki,et al.  p53 mediates the suppression of cancer cell invasion by inducing LIMA1/EPLIN. , 2017, Cancer letters.

[14]  Alex Boussioutas,et al.  Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients , 2016, Oncotarget.

[15]  W. Jiang,et al.  Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer. , 2016, International journal of oncology.

[16]  W. Jiang,et al.  EPLIN: a fundamental actin regulator in cancer metastasis? , 2015, Cancer and Metastasis Reviews.

[17]  W. Jiang,et al.  WISP-2 in human gastric cancer and its potential metastatic suppressor role in gastric cancer cells mediated by JNK and PLC-γ pathways , 2015, British Journal of Cancer.

[18]  Yan Li,et al.  15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer. , 2015, International journal of clinical and experimental pathology.

[19]  Q. Guan,et al.  Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction: A Meta-Analysis , 2015, Journal of clinical gastroenterology.

[20]  S. Hattori,et al.  Epithelial protein lost in neoplasm modulates platelet-derived growth factor-mediated adhesion and motility of mesangial cells. , 2014, Kidney international.

[21]  L. Zhang,et al.  Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy , 2013, British Journal of Cancer.

[22]  Xu Wang,et al.  Epidermal Growth Factor Promotes Protein Degradation of Epithelial Protein Lost in Neoplasm (EPLIN), a Putative Metastasis Suppressor, during Epithelial-mesenchymal Transition* , 2012, The Journal of Biological Chemistry.

[23]  W. Jiang,et al.  Expression Profile of Epithelial Protein Lost in Neoplasm-Alpha (EPLIN-α) in Human Pulmonary Cancer and Its Impact on SKMES-1 Cells in Vitro , 2012 .

[24]  W. Jiang,et al.  EPLIN is a negative regulator of prostate cancer growth and invasion. , 2011, The Journal of urology.

[25]  P. Nelson,et al.  EPLIN Downregulation Promotes Epithelial-Mesenchymal Transition in Prostate Cancer Cells and Correlates With Clinical Lymph Node Metastasis , 2011, Oncogene.

[26]  R. Hoffmann,et al.  Epithelial Protein Lost in Neoplasm α (Eplin-α) is transcriptionally regulated by G-actin and MAL/MRTF coactivators , 2010, Molecular Cancer.

[27]  R. Mansel,et al.  Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome , 2008, Molecular Cancer.

[28]  T. Pollard,et al.  EPLIN regulates actin dynamics by cross-linking and stabilizing filaments , 2003, The Journal of cell biology.

[29]  D. Chang,et al.  Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. , 2002, Molecular biology of the cell.

[30]  D. Chang,et al.  Characterization of mouse epithelial protein lost in neoplasm (EPLIN) and comparison of mammalian and zebrafish EPLIN. , 2001, Gene.

[31]  D. Chang,et al.  Characterization of the human EPLIN (Epithelial Protein Lost in Neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. , 2000, Gene.

[32]  D. Chang,et al.  EPLIN, Epithelial protein lost in neoplasm , 1999, Oncogene.

[33]  S. Nelson,et al.  Characterization of transformation related genes in oral cancer cells , 1998, Oncogene.

[34]  M. Takeichi,et al.  Inaugural Article: EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt , 2008 .